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Abstract 
We investigated antinociceptive activity of botulinum toxin type A (BTX-A) in a model of 
diabetic neuropathic pain in rats.  
Male Wistar rats were made diabetic by a single intraperitoneal injection of streptozotocin (80 
mg/kg). Sensitivity to mechanical and thermal stimuli was measured with the paw-pressure 
and hot-plate test, respectively. The formalin test was used to measure sensitivity to chemical 
stimuli. Diabetic animals with pain thresholds lower for at least 25% compared to the non-
diabetic group were considered neuropathic and were injected with BTX-A either 
subcutaneously (3, 5 and 7 U/kg) or intrathecally (1 U/kg). Mechanical and thermal sensitivity 
was measured at several time-points.  
After peripheral application, BTX-A (5 and 7 U/kg) reduced mechanical and thermal 
hypersensitivity not only on ipsilateral, but on contralateral side, too. The antinociceptive 
effect started 5 days following BTX-A injection and lasted at least 15 days. Formalin induced 
hypersensitivity in diabetic animals was abolished as well. When applied intrathecally, BTX-
A (1 U/kg) reduced diabetic hyperalgesia within 24 h supporting the assumption of retrograde 
axonal transport of BTX-A from the peripheral site of injection to central nervous system. 
The results presented here demonstrate the long-lasting pain reduction after single BTX-A 
injection in the animals with diabetic neuropathy. The bilateral pain reduction after unilateral 
toxin application and the effectiveness of lower dose with the faster onset after the intrathecal 
injection suggest the involvement of the central nervous system in the antinociceptive action 
of BTX-A in painful diabetic neuropathy. 
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1. Introduction 
Chronic polyneuropathy is present in 8–26% of diabetic patients and represents a major health 
problem with substantial impact on the quality of life. It is the most common late diabetic 
complication and affects both type 1 and type 2 diabetic patients but it is more frequent and 
severe in the type 1 (Sima et al., 2006). Antidepressants, carbamazepine, gabapentin, opioids 
and, more recently, duloxetine and pregabalin are used in treatment of painful diabetic 
neuropathy (Ziegler, 2008). None of these drugs or their combinations provide complete or 
long-lasting pain relief. Side effects, poor tolerability and ineffectiveness for some percent of 
diabetic patients are major disadvantages of the current therapeutic options (Ziegler, 2008).  
Botulinum toxin type A (BTX-A) cleaves SNAP-25 (synaptosomal associated protein of 25 
kDa), one of the SNARE proteins essential for neurotransmitter release (Aoki, 2005; Grumelli 
et al., 2005) and it is nowadays widely used to treat muscular spasms (Truong and Jost, 2006). 
Additionally, it was observed that BTX-A reduced pain in conditions not associated with 
muscle hypercontraction, like migraine (Göbel, 2004), trigeminal neuralgia (Allam et al., 
2005), chronic focal neuropathies (Ranoux et al., 2008) and low-back pain (Jabbari, 2008). 
Several experiments on animals demonstrated the antinociceptive effect of BTX-A on 
inflammatory pain induced by formalin (Cui et al. 2004), carrageenan and capsaicin (Bach-
Rojecky and Lacković, 2005a). The pain reduction after single subcutaneous BTX-A injection 
was demonstrated in experimental models of peripheral neuropathic pain (Bach-Rojecky et 
al., 2005b; Luvisetto et al., 2006; Park et al., 2006; Favre-Guilmard et al., 2009). The 
antinociceptive action of BTX-A was independent of the effect on muscle relaxation.  Hence, 
there is a possibility that BTX-A might be a useful long-lasting treatment in painful diabetic 
neuropathy. Yuan et al. (2009) recently showed that single local injections of BTX-A reduced 
pain scores on visual analogue scale in 18 diabetic patients within 3 months after the 
injection.  
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The most commonly used model of diabetic neuropathy are rodents with type 1 diabetes 
induced by the pancreatic β-cell toxin streptozotocin (Calcutt, 2004). Diabetic animals display 
physiologic, neurochemical and behavioural changes suggestive of altered pain perception. 
Only behavioural methods can directly distinguish painful (hyperalgesia or allodynia) from 
non-painful sensation. The most common behavioural tests measure changes in sensitivity to 
mechanical, thermal and chemical noxious stimuli (Calcutt, 2004).  
In the present study we investigated antinociceptive activity of BTX-A in a model of diabetic 
neuropathic pain in rats.  
 
2. Materials and methods 
2.1. Animals 
Male Wistar rats (University of Zagreb, School of Medicine) weighing 250-300 g were used. 
Animals were housed in wire-bottomed cages (4-5 per cage) with free access to food and 
water. The experiments were carried out according to the Croatian Act on Animal Welfare 
and the National Institutes of Health Guide for Care and Use of Laboratory Animals 
(Publication No. 85-23, revised 1985). The experiments were approved by the Ethical 
Committee of the University of Zagreb, School of Medicine (permit No. 07-76/2005-43). 
2.2. Drugs 
The following drugs were used: chloral hydrate, streptozotocin and formalin (Sigma, St. 
Louis, MO, USA); BTX-A (BOTOX, Allergan, Irvine, CA, USA). Each vial of BOTOX 
contains 100 U (~4.8 ng) of purified Clostridium botulinum type A neurotoxin complex. To 
obtain respective doses, BTX-A was reconstituted in adequate volume of 0.9% saline.  
2.3. Induction of diabetes 
Rats were injected by a single intraperitoneal (i.p.) injection of freshly dissolved 
streptozotocin in citrate buffer (pH 4.5) at a dose of 80 mg/kg body weight. Control animals 
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were injected i.p. with the citrate buffer. Tail-vein blood-glucose concentration was 
determined by colorimetric PAP method 5 days following the induction of diabetes. Animals 
with the blood glucose concentration above 15 mmol/l were considered diabetic and were 
included in the study. Hyperglycaemia was re-confirmed before nociceptive measurement (3 
weeks after streptozotocin injection). 
2.4. Nociceptive tests 
2.4.1. Mechanical sensitivity measurement 
The sensitivity to mechanical stimuli was measured by the paw-pressure test as described by 
Randall and Selitto (1957). Mechanical nociceptive thresholds expressed in grams were 
measured 3 times in 10-min intervals by applying increased pressure to the dorsal surface of 
the hindpaw until paw-withdrawal or overt struggling were elicited. The measurements were 
performed bilaterally.  Measurements were done by an experimenter who was not aware of 
the treatment groups. 
2.4.2. Thermal sensitivity measurement 
Thermal sensitivity was tested using a slight modification of the unilateral hot-plate test 
originally described for mice (Mendez et al., 2002). The temperature of the hot-plate surface 
was 520.5 C and the cut off time was 20 s in order to prevent paw-tissue damage. Rats were 
gently restrained and the plantar side of the tested paw was placed on the hot-plate surface. 
The latency of paw withdrawal from the heated surface was recorded 3 times at 10-min 
intervals. The measurements were performed bilaterally.  Measurements were done by an 
experimenter who was not aware of the treatment groups. 
2.4.3. Chemical sensitivity measurement 
Formalin (5%), in a volume 50 μl was injected subcutaneously (s.c.) into the plantar region of 
the right hindpaw. Immediately after the injection, the number of flinches and shakes of the 
injected paw was counted in 2-min intervals for 1 h (Kang et al., 2007). In the present study, 
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the data collected between 0 and 15 min after the formalin injection represented phase 1 and 
the data collected between 15 and 60 min after the formalin injection represented phase 2. 
Behavioural studies were performed by an experimenter who was not aware of the treatment 
groups. Results are presented as the sum of the total number of flinches/shakes of the formalin 
injected paw during each phase. 
2.5. BTX-A injections 
BTX-A was injected by two different routes of administration: 1.) s.c. into the plantar surface 
of the hindpaw to conscious rat in a volume of 20 l with a 27 ½ gauge syringe; and 2.) 
intrathecally at L3-L4 level to anaesthetised rat (chloral hydrate 300 mg/kg, i.p.) in a volume 
of 10 µl using a Hamilton syringe. 
2.6. Experimental protocol 
Diabetic animals were subjected to bilateral measurements of sensitivity to mechanical and 
thermal stimulation 3 weeks following the induction of diabetes. Only those diabetic animals 
with nociceptive threshold at least 25% lower than the one found in control non-diabetic 
group were considered neuropathic (hyperalgesic) and were then subjected to the BTX-A or 
saline treatment.  
Dose-response experiment: BTX-A at doses 3, 5 and 7 U/kg was applied peripherally into the 
hindpaw pad. Sensitivity to thermal and mechanical stimuli was measured bilaterally 5 days 
following the toxin application. Formalin test was performed only once (10-12 days following 
the BTX-A peripheral injection). 
The time-course experiment: BTX-A in a dose of 7 U/kg was applied peripherally and 
mechanical sensitivity was measured ipsilaterally on day 1, 5, 15 and 28 following the BTX-
A peripheral injection.   
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Intrathecal application: BTX-A 1U/kg was applied into the lumbar spinal fluid (central 
application) and the effects on mechanical and thermal hyperalgesia were tested bilaterally on 
day 1, 5, 12, 20, 27, 33 and 37.  
2.7. Statistical analysis 
Results are presented as mean ± standard error (S.E.M.). Statistical analysis was performed by 
an analysis of variance (ANOVA). Intergroup differences were analyzed by the Newman-
Keuls post hoc test. A P<0.05 was considered significant. In the time-course experiment, 
ANOVA for repeated measurements followed by Tukey’s test was employed. 
 
3. Results 
Three weeks following a single i.p. streptozotocin injection (80 mg/kg), about 45% of rats 
with diabetes (blood glucose concentration >15 mmol/l) developed increased sensitivity to 
mechanical and thermal stimuli compared to the saline-treated non-diabetic control group. 
Those animals were included in further experiments as groups with neuropathic pain. In those 
animals a single unilateral BTX-A (5 and 7 U/kg) injection into the right hindpaw pad 
significantly decreased mechanical hypersensitivity not only on ipsilateral, but on the 
contralateral side, as well (Fig.1.).  
 
Fig. 1.  
 
In contrast to the mechanical hyperalgesia which was consistent throughout the whole 
experiment, changes in the thermal sensitivity were variable. Peripheral injection of BTX-A 
in a dose of 7 U/kg significantly reduced thermal hypersensitivity on ipsilateral side only. On 
the contralateral side, sensitivity to thermal stimulation in rats with diabetes seemed increased 
compared to non-diabetic animals, but this was not significant probably due to the large inter-
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group variability. Although BTX-A 7 U/kg appeared to have reversed the thermal latency on 
the contralateral side, this was not significant either (Fig. 2.).  
 
Fig. 2.  
 
Formalin injection into the ipsilateral hindpaw of diabetic rats induced significant increase in 
the number of flinches and shakes of the injected paw compared to non-diabetic control only 
in phase 2 of the test (Fig. 3A and 3B). All three tested doses of BTX-A significantly 
decreased formalin-induced pain in the second phase of the test (Fig. 3A).  
 
Fig. 3 
 
BTX-A decreased mechanical hypersensitivity 5 days following application into the hindpaw 
pad and the effect remained significant for 10 more days. When tested 1 day after the 
injection into the hindpaw, BTX-A was ineffective (Fig. 4.).  
 
Fig. 4.  
 
 
BTX-A injected intrathecally in the dose of 1 U/kg into the lumbar cerebrospinal fluid 
decreased bilateral thermal and mechanical hypersensitivity within 24 h after the application. 
The antinociceptive effect was significant even on day 27 for the thermal (Fig. 5A.) and on 
day 33 for the mechanical hyperalgesia (Fig. 5B.). 
 
 
Fig. 5.  
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4. Discussion 
In the present study we demonstrate the long-lasting reduction of hyperalgesia in 
experimental diabetic neuropathy after single BTX-A peripheral and central injection. In 
contrast to all other forms of existing short-lasting therapy, antinociceptive effect of BTX-A 
in the present experiments lasted up to four weeks. The bilateral pain reduction after unilateral 
toxin application and the effectiveness of lower dose with the faster onset after the intrathecal 
injection suggests the involvement of the CNS in the BTX-A antinociceptive action.  
The pathology of diabetic neuropathy is characterized by progressive nerve fibre loss and 
endoneurial microangiopathic changes (Calcutt et al., 2007). Pathogenesis, believed to be the 
most important, consists of an ischemic process secondary to microangiopathy, glycosylation 
of structural proteins consequent to chronic hyperglycemia, or injury by reactive oxygen 
species generated by altered glucose metabolism (Leinninger et al., 2006; Romanovsky et al., 
2004).  However, all recent knowledge is not sufficient to explain the appearance of hyper- 
and hyposensitivity to pain during the course of diabetic neuropathy.   
Streptozotocin is the most common substance used for the induction of diabetes in the 
rodents. The cytotoxic action of streptozotocin is mediated by reactive oxygen species, 
liberation of the toxic amounts of NO, alkylation and damage of DNA which result in rapid 
destruction of pancreatic -cells (Szkudelski, 2001). Diabetic polyneuropathy develops within 
weeks of diabetes induction and it is characterized by nerve conduction velocity 
abnormalities, increased activity of the polyol pathway, and decreased endoneurial blood 
flow. However, despite these early functional and metabolic abnormalities, animals do not 
develop structural deficits, such as progressive nerve fibre loss, even after prolonged duration 
of diabetes, which is the very hallmark of human diabetic polyneuropathy (Calcutt and 
Backonja, 2007).  
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Neuropathic pain after single i.p. streptozotocin injection in rodents is mostly characterized by 
mechanical allodynia and hyperalgesia which progressively develop within 2 weeks. 
Inconsistent changes in the thermal nociceptive thresholds have been reported in diabetic 
animals: thermal hyperalgesia (Courteix et al., 1993), thermal hypoalgesia (Apfel et al., 1994) 
to unchanged thermal sensitivity (Malcangio and Tomlinson, 1998). It has also been reported 
that diabetic rats exhibit transient thermal hyperalgesia during the first two weeks of diabetes, 
which progresses to thermal hypoalgesia within next 2-3 months, similarly to what has been 
found in diabetic patients (Calcutt, 2004). In our experiments, 3 weeks after the streptozotocin 
injection less than 50% of animals with diabetes developed mechanical and thermal 
hyperalgesia. Contrary to the mechanical hyperalgesia, we found that changes in the thermal 
sensitivity were less pronounced and inconsistent. In the present experiment, unilateral BTX-
A (5 and 7 U/kg) injection into the rat hindpaw pad reduced mechanical hyperalgesia on 
ipsilateral injected side but on the contralateral side as well. The bilateral effect was started to 
be evident on day 5 after the toxin peripheral injection. In this, as well as in our previous 
experiments, antinociceptive effect of BTX-A was achieved in doses several times lower than 
the doses required to produce any measurable effect on motor performance (Cui et al., 2004, 
Favre-Guimard et al., 2009) or any visible behavioral effect. In our previous experiments we 
repeatedly questioned the role of the peripheral sensory nerve endings and speculated about 
the involvement of the CNS in the antinociceptive effect of BTX-A (Bach-Rojecky and 
Lacković, 2005a; Bach-Rojecky et al., 2008). In our most recent report, unilateral injection of 
BTX-A bilaterally abolished “mirror pain” induced with repeated acidic saline injection thus 
indicating involvement of the CNS (Bach-Rojecky and Lacković, 2009). Moreover, the 
antinociceptive effect of BTX-A was completely prevented by colchicine pre-treatment, 
additionally suggesting that the central effect is mediated by retrograde axonal transport of 
BTX-A into the CNS (Bach-Rojecky and Lackovic, In Press). At the same time, the bilateral 
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effect of unilateral BTX-A injection was observed in the paclitaxel induced neuropathy in rats 
(Favre-Guilmard et al. 2009). The authors assumed that the antinociceptive action of BTX-A 
is not due to a local effect.  Measuring SNAP-25 cleavage at different brain regions 
Antonucci et al. (2008) recently demonstrated retrograde axonal transport of BTX-A via 
central neurons and motoneurons and thus offered novel pathways of BTX-A trafficking 
within neurons. Moreover, after tectal injections of the toxin, cleaved SNAP-25 appeared in 
cholinergic synapses in the retina. According to the authors, this data indicates retrograde 
transport to retinal ganglion cells, followed by transcytosis into starbust amacrine cells. In our 
experiments, BTX-A is most probably transported to the central terminal of the ipsilateral 
afferent fiber. However, how BTX.A exerts antinociceptive action on a contralateral side 
remains highly speculative. One of the possibilities might be that it is transynaptically 
transported to the central endings of the afferent neurons on the contralateral side. However, 
other possibilities cannot be ruled out, including other places of action with effect on 
contralateral side. While the significance of axonal transport in the peripheral motoneurons 
and central neurons is not clear (Antonucci et al. 2008), we suggested the existence of axonal 
transport of BTX-A most probably within sensory neurons mediating antinociceptive effect of 
BTX-A.  
In order to further investigate involvement of the central nervous system in the 
antinociceptive effect of BTX-A , we investigated it’s effect after intrathecal injection. 
Intrathecal injection of BTX-A abolished the mechanical and thermal hypersensitivity in 
diabetic rats in a dose as low as 1 U/kg (10 µl). The effect was bilateral and started within the 
first 24 h. The observed effectiveness of lower dose and its faster onset after the intrathecal 
application additionally support the central origin of the BTX-A antinociceptive action.  
In our experiments the effect lasted at least 15 days after single peripheral BTX-A injection 
and up to 33 days when BTX-A was applied intrathecally.  
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Chemical hypersensitivity was reported to develop in rats with streptozotocin-induced 
diabetes. The formalin test is used to investigate spinal sensitization in animals and allows 
investigation of sensory processing beyond peripheral nociceptive pathways (Calcutt and 
Backonja, 2007). Chemical hyperalgesia during phase 2 of the formalin test in diabetic rats is 
associated with increased cyclooxygenase-2 expression and prostaglandine E-2 release in the 
spinal cord (Freshwater et al., 2002; Ramos et al., 2007). Formalin also increased the 
expression of postsynaptic NMDA and AMPA receptors for glutamate (Li et al., 1999) and 
enhanced electrophysiologic activity in the dorsal horn neurons (Chen and Pan, 2002). Spinal 
amplification of pain signals with paradoxical reduction in ongoing signals from the periphery 
(Calcutt et al., 2000) and decreased spinal release of glutamate (Malmberg et al., 2006) 
suggest significant role of central sensitization in the formalin induced hypersensitivity in 
experimental diabetes. Although the investigation of neuropathic pain in diabetes has 
primarily focused on the peripheral nerves, growing body of evidence suggests spinal cord 
and higher CNS as generators and amplifiers of pain (Calcutt and Backonja, 2007).  
In the present experiment, BTX-A applied peripherally into the rat hindpaw pad 10-12 days 
before the injection of formalin completely reduced chemical hypersensitivity in diabetic rats 
for several weeks. Two previously mentioned experiments (Bach-Rojecky and Lacković, 
2009, Favre-Guilmard et al., 2009) and the experiments presented here cannot be explained in 
any other way but assuming the involvement of the CNS. Although the mechanism of the 
long-lasting antinociceptive effect of BTX-A is not clear, discovery of the axonal transport of 
BTX-A in motoneurons (Antonucci et al., 2008) and, possibly, in sensory neurons as well 
(Bach-Rojecky and Lacković, 2009) provide a necessary prerequisite for central action of 
BTX-A. We believe that the antinociceptive effect of BTX-A might be associated with 
processes of central sensitization. 
5. Conclusion 
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At the same time the results presented here, together with the observation of Yuan et al. 
(2009) on a small number of diabetic patients, demonstrate the potential of BTX-A as a 
therapeutic tool to combat neuropathic pain.  
Acknowledgements 
A part of this manuscript was presented at 58th Annual American Academy of Neurology, 
San Diego, USA, 2006. We are grateful to Bozica Hržan for her excellent technical 
assistance. We also acknowledge the support of the Croatian Ministry of Science, Education 
and Sport (Project No. 108-1080003-0001 and 108-1080003-0020) and Deutscher 
Akademischer Austausch Dienst (DAAD).  
 
References 
Allam, N., Brasil-Neto, J.P., Broen, G., Tomaz, C., 2005. Injections of botulinum toxin type 
A produce pain alleviation in intractable trigeminal neuralgia. Clin. J. Pain 21, 182-184. 
Antonucci, F., Rossi, C., Gianfrancesci, L., Rosetto, O., Calleo, M., 2008. Long-distance 
retrograde effects of botulinum neurotoxin A. J. Neurosci. 28, 3689-3696.  
Aoki, K.R., 2005. Review of a proposed mechanism for the antinociceptive action of 
botulinum toxin type A. Neurotoxicology 26, 785-793. 
Apfel, S.C., Arezzo, J.C., Brownlee, M., Federoff, H., Kessler, J.A., 1994. Nerve growth 
factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 
634, 7-12. 
Bach-Rojecky, L., Lacković, Z., 2005a. Antinociceptive effect of botulinum toxin type A in 
rat model of carrageenan and capsaicin induced pain. Croat. Med. J. 46, 201-208. 
Bach-Rojecky, L., Relja, M., Lacković, Z., 2005b. Botulinum toxin type A in experimental 
neuropathic pain. J. Neural Transm. 112, 215-219. 
 15
Bach-Rojecky, L., Dominis, M., Lackovic, Z., 2008. Lack of anti-inflammatory effect of 
botulinum toxin type A in experimental models of inflammation. Fund. Clin. Pharmacol. 22, 
503-509. 
Bach-Rojecky, L., Lacković, Z., 2009. Central origin of the antinociceptive action of 
botulinum toxin type A. Pharmacol. Biochem. Behav. 94, 234-238.  
Calcutt, N.A., 2004. Experimental models of painful diabetic neuropathy. J. Neurol. Sci. 220, 
137-139. 
Calcutt, N.A., Backonja, M., 2007. Pathogenesis of pain in peripheral diabetic neuropathy. 
Curr. Diab. Rep. 7, 429–434. 
Calcutt, N.A., Stiller, C., Gustafsson, H., Malmberg, A.B., 2000. Elevated substance P like 
immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic 
rats. Brain Res. 856, 20-27. 
Chen, S.R., Pan, H.L., 2002. Hypersensitivity of spinothalamic tract neurons associated with 
diabetic neuropathic pain in rats. J. Neurophysiol. 87, 2726-2733.  
Courteix, C., Eschalier, A., Lavarenne, V., 1993. Streptozotocin-induced diabetic rats: 
behavioural evidence for a model of chronic pain. Pain 53, 81-88. 
Cui, M., Khanijou, S., Rubino, J., Aoki, K.R., 2004. Subcutaneous administration of 
botulinum toxin A reduces formalin-induced pain. Pain 107, 125-133. 
Favre-Guimard, C., Auguet, M., Chabrier, P-E., 2009. Different antinociceptive effects of 
botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models, Eur. J. 
Pharmacol. 617, 48-53. 
Freshwater, J.D., Svensson, C.I., Malmberg, A.B., Calcutt, N.A., 2002. Elevated spinal 
cyclooxigenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51, 
2249-2255. 
Göbel, H., 2004. Botulinum toxin in migraine prophylaxis. J. Neurol. 251, I8-I11. 
 16
Grumelli, C., Verderio, C., Pozzi, D., Rossetto, O., Montecucco, C., Matteoli, M., 2005. 
Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 26, 
761-767. 
Jabbari, B., 2008. Evidence based medicine in the use of botulinum toxin for back pain. 
J. Neural Transm. 115, 37-640. 
Kang, S., Kim, C.H., Lee, H., Kim, D.Y., Han, J.I., Chung, R.K. et al., 2007. Antinociceptive 
synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat 
formalin test. Anesth. Analg. 104, 719-725. 
Leinninger, G.M., Edwards, J.L., Lipshaw, M.J., Feldman, E.L., 2006. Mechanisms of 
disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat. Clin. Pract. 
Neurol. 2, 620-628.  
Li, N., Young, M.M., Bailey, C.J., Smith, M.E., 1999. NMDA and AMPA glutamate receptor 
subtypes in the thoracic spinal cord ion lean and obese-diabetic ob/ob mice. Brain Res. 849, 
34-44. 
Luvisetto, S., Marinelli, S., Lucchetti, F. et al., Marchi, F., Cobianchi, S., Rosetto, O., 
Montecucco, C., Pavone, F., 2006. Botulinum neurotoxins and formalin-induced pain: central 
vs. peripheral effects in mice. Brain Res.1082, 124-131. 
Malcangio, M., Tomlinson, D.R., 1998. A pharmacological analysis of mechanical 
hyperalgesia in streptozotocin diabetic rats. Pain 76, 151-157. 
Malmberg, A.B., O’Connor, W.T., Glennon, J.C., Cesena, R., Calcutt, N.A., 2006. Impaired 
formalin-evoked changes of spinal amino acid levels in diabetic rats. Brain Res. 1115, 48–53.  
Menendez, L., Lastra, A., Hidalgo, A., Baamonde, A., 2002. Unilateral hot-plate test: a simple 
and sensitive method for detecting central and peripheral hyperalgesia in mice. J. Neurosci. 
Methods 113, 91-97. 
 17
Park, H.J., Lee, Y., Lee, J., Park, C., Moon, D.E., 2006. The effects of botulinum toxin A on 
mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesthes. 53, 470-
477. 
Ramos, K.M., Jiang, Y., Svensson, C.I., Calcutt, N.A., 2007. Pathogenesis of spinally 
mediated hyperalgesia in diabetes. Diabetes 56, 1569-1576. 
Randall, L.O., Selitto, J.J., 1957. A method for measurement of analgesic activity on 
inflammed tissue. Arch. Internat. Pharmacodyn. Ther. 111, 409-419. 
Ranoux, D., Attal, N., Morain, F., Bouhassira, D., 2008. Botulinum toxin type A induces 
direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64, 274-283. 
Romanovsky, D., Hastings, S.L., Stimers, J.R., Dobretsov, M., 2004. Relevance of 
hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J. 
Peripher. Nerv. Syst. 9, 62–69. 
Sima, A.A.F., Kamiya, H., 2006. Diabetic neuropathy differs in type 1 and type 2 diabetes. 
Ann. N.Y. Acad. Sci. 1084, 235-249.  
Szkudelski, T., 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat 
pancreas. Physiol. Res. 50, 536-546. 
Truong, D.D., Jost, W.H., 2006. Botulinum toxin: clinical use. Parkinsonism Relat. Disord.  
12, 331-355. 
Yuan, R.Y., Sheu, J.J., Yu, J.M., Chen, W.T., Tseng, I.J., Chang, H.H., Hu, C.J., 2009. 
Botulinum toxin for diabetic neuropathic pain. A randomized double-blind crossover trial. 
Neurology 72, 1473-1478. 
Ziegler, D., 2008. Painful diabetic neuropathy: treatment and future aspects. 
Diab.Metab.Res.Rev. 24, S52-S57.  
 18
Fig. 1. Dose dependent effect of BTX-A on streptozotocin-induced mechanical hyperalgesia 
on ipsilateral and contralateral side of the rat hindpaw. Measurements were done 5 days 
following BTX-A s.c. injection into the hindpaw pad. Results are presented as meanS.E.M., 
n=5-7. *P<0.01, **P<0.001 (Newmann-Keuls post hoc test). Legend: Non-diabetic control 
stands for the animals without diabetes injected only with citrate buffer. Saline denotes 
animals with diabetic neuropathy injected with saline into the hindpaw pad; BTX-A 3, 5 and 7 
U/kg denote animals with diabetic neuropathy injected with BTX-A 3, 5 or 7 U/kg. 
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Fig. 2. Dose dependent influence of BTX-A on streptozotocin-induced thermal sensitivity on 
ipsilateral and contralateral side of the rat hindpaw. Measurements were done 5 days 
following BTX-A s.c. injection into the hindpaw pad. Results are presented as meanS.E.M., 
n=5-7. *P<0.01; **P<0.001 (Newmann-Keuls post hoc test). Legend: Non-diabetic control 
stands for the animals without diabetes injected only with citrate buffer. Saline denotes 
animals with diabetic neuropathy injected with saline into the hindpaw pad; BTX-A 3, 5 and 7 
U/kg denote animals with diabetic neuropathy injected with BTX-A 3, 5 or 7 U/kg. 
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Fig. 3. BTX-A peripheral injection reduces formalin-induced pain in streptozotocin diabetic 
rats. Measurements were done 10-12 days following BTX-A peripheral application into the 
hindpaw. Results are presented as mean±S.E.M. for the second phase of the formalin test 
(3A), n=5-6. *P<0.05, **P<0.001 (Newman-Keuls post hoc test).  Results are presented as 
mean±S.E.M. for every 4-min interval during 60 min of testing, n=5-6. *P<0.05; **P<0.01; 
***P<0.001 compared to non-diabetic control; +P<0.05; ++P<0.01 compared to diabetic 
neuropathy +saline (Newman-Keuls post hoc test). 
Legend: Non-diabetic control stands for the animals without diabetes injected only with 
citrate buffer. Saline denotes animals with diabetic neuropathy injected with saline into the 
hindpaw pad; BTX-A 3, 5 and 7 U/kg denote animals with diabetic neuropathy injected with 
BTX-A 3, 5 or 7 U/kg. 
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Fig. 4. The time-dependent influence of peripheral BTX-A 7 U/kg injection into the hindpaw 
on mechanical hyperalgesia in rats with streptozotocin-induced diabetes. Results are presented 
as mean±S.E.M., n=5-6. *P<0.001 compared to non-diabetic control; +P<0.05, ++P<0.01 
compared to saline-treated rats with diabetic neuropathy (ANOVA for repeated measurements 
and Tukey’s post hoc test). 
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Fig. 5. Time-dependent influence of intrathecal BTX-A 1 U/kg injection on thermal (A) and 
mechanical (B) hyperalgesia in rats with streptozotocin-induced diabetes. Results are 
presented as mean±S.E.M., n=5-6. *P<0.001 compared to non-diabetic control; +P<0.05, 
++P<0.01, +++P<0.001 compared to saline-treated rats with diabetic neuropathy (ANOVA for 
repeated measurements and Tukey’s post hoc test).  
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